Clinical Trial Update: Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating GSK3359609 in combination with pembrolizumab for PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• GSK3359609
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Head and Neck | Phase 3 | Status: TERMINATED | Results posted: 2022-05-24